Issue Date: March 27, 2017 | Web Date: March 23, 2017
Trump’s plan to raise FDA user fees conflicts with agency-industry deal
The U.S. Congress is gearing up to reauthorize the Food & Drug Administration’s ability to collect fees from drug manufacturers. FDA and the pharmaceutical industry have already worked out an agreement regarding fees for fiscal 2018 to 2022. But that plan is now up in the air because President Donald J. Trump wants to boost FDA user fees by $1 billion in fiscal 2018.
Lawmakers must renew FDA’s authority to collect fees from industry every . . .
To view the rest of this content, please log in with your ACS ID.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society